PDF, Patent Landscape Report on Atazanavir - WIPO

More documents

Recommendations

Info

CATEGORIES WITH HIGHEST EMPHASISWhen the entire collection is compared by category, and the categories with the highestemphasis within each assignee group is noted, similarities and differences in assigneeemphasis can be noted (Figure 24).The commercial entities are relatively similar in chemical and formulation emphasis, withtheir highest focus on synthesis, and stereospecific synthesis in particular. Most of the drugcandidates for this target (viral protease) are peptide mimetics which must stereospecificallybind to a site on the surface of the target. Commercial focus on this issue is understandablesince the efficacy, cost of goods and reduction of side-effects all rest on the effectiveness ofstereospecific synthesis of a drug with multiple stereoisomeric centers (molecular linkageswhich are required to be in the appropriate orientation, left-handed or right-handed).In the area of combinations, Novartis/BMS places slightly more emphasis on combinationswith other protease inhibitors and reverse transcriptase inhibitors than with integrase. It alsoemphasizes auto-immune indications and cancer but there is little evidence of pursuit ofneurologic or other anti-viral indications.Figure 24. Emphasis on Categories in Drug DevelopmentChemistryCombinationsFormulationsIndicationsCOMPARING TECHNICAL EMPHASIS OF TOP COMPANIESThe categories listed above allowed creation of a matrix (Figure 25) that compares eachcompany for activity in different technical areas. The companies selected for the matrix area sampling (44 of 288) of the full list available in Appendix B, and include those companiesthat have an approved HIV-protease inhibitor drug.30
Figure 25. Emphasis Matrix for Selected AssigneesIn Figure 24, the darker colors highlight thetop values in each column. The companieswho have an approved HIV proteaseinhibitor (PI) drug are quite dominant withthe exception of Roche, and interestingobservations can be made about manycompanies.Abbott and its collaborator Enanta, and to alesser degree Gilead and Schering) areinterested in serine proteases becauseserine protease inhibitors are useful inHepatitis C therapy. Abbott and Gilead usethe serine protease inhibitors in combinationtherapy for patients with both HIV and HCV,while Schering appears to be more focusedon HCV per se.Cytovia is interested in drugs inducingapoptosis for cancer treatment (includingKaposi’s sarcoma), and they mentioncombination therapies with these drugs andPI and reverse transcriptase (RTI) drugs.There are companies in the matrix that haveno patents mentioning indications at all.These companies form an interesting subset(Concert, Aicuris, Nektar, Ranbaxy,Progenics) that includes suppliers ofintermediates, and developers of improvedprocesses or formulations that could positionthem to be generic suppliers when the drugsare off-patent.31
Page 4 and 5: ContentsSECTION 1: THE TWO OBJECTIV
Page 7 and 8: collection for nuggets of intellige
Page 9 and 10: CHEMICAL NAMINGChemical naming conv
Page 11 and 12: Figure 2: Legal Status for Novartis
Page 13 and 14: name, but after the patent protecti
Page 15 and 16: STAGE TWO CLINICAL SEARCHTo be more
Page 17 and 18: CLINICAL COLLECTIONThis is an examp
Page 19 and 20: THE FOUNDER PATENT AND ITS DOWNSTRE
Page 21 and 22: CHEMICAL COLLECTIONThis is an examp
Page 23 and 24: SECTION 5: GENERAL OVERVIEW OF THE
Page 25 and 26: FAMILY MEMBER COUNTRIESLooking at p
Page 27 and 28: The crossover between categories is
Page 29 and 30: THE DEVELOPER’S OWN TIMELINEThe A
Page 31: Several of the representative paten
Page 35 and 36: PATENT QUALITY INDICATORS FOR SELEC
Page 37 and 38: Figure 30. References made by the F
Page 39 and 40: FORMULATIONSEven before a drug is a
Page 41 and 42: Figure 34. References to Bristol My
Page 43 and 44: PROPRIETARY DRUGS AND LITIGATIONThe
Page 45 and 46: TWO DRUGS DIRECTED AT THE SAME TARG
Page 47 and 48: Citations to this document mainly c
Page 49 and 50: USING OVERLAP TO FIND COMBINATIONS
Page 51 and 52: INTERNATIONAL PATENT CLASSIFICATION
Page 53 and 54: ased on the IPC, but with sometimes
Page 55 and 56: DERWENT MANUAL CODESDWPI Manual Cod
Page 58: For more information contact WIPO a

PDF, Patent Landscape Report on Atazanavir - WIPO

Create successful ePaper yourself

Delete template?

Save as template?